Thrombosis and Haemostasis
Papers 10,000
1 page of 1,000 pages (10k results)
#1Ilia Makedonov (SHSC : Sunnybrook Health Science Centre)H-Index: 1
#2Susan R. Kahn (McGill University)H-Index: 67
Last. Jean Philippe Galanaud (SHSC : Sunnybrook Health Science Centre)
view all 7 authors...
The post thrombotic syndrome (PTS) is chronic venous insufficiency secondary to a prior deep vein thrombosis (DVT). It is the most common complication of VTE and, while not fatal, it can lead to chronic, unremitting symptoms as well as societal and economic consequences. The cornerstone of PTS treatment lies in its prevention after DVT. Specific PTS preventative measures include the use of elastic compression stockings (ECS) and pharmacomechanical catheter directed thrombolysis (PCDT). However, ...
#1Jamie Kane (VUMC: Vanderbilt University Medical Center)
#2Matthijs F. Jansen (VUMC: Vanderbilt University Medical Center)H-Index: 1
Last. Esther Lutgens (LMU: Ludwig-Maximilians-Universität München)H-Index: 30
view all 15 authors...
Galectins have numerous cellular functions in immunity and inflammation. Short-term galectin-2 blockade in ischaemia-induced arteriogenesis shifts macrophages to an anti-inflammatory phenotype and improves perfusion. Galectin-2 may also affect other macrophage related cardiovascular diseases. This study aims to elucidate the effects of Galectin-2 inhibition in atherosclerosis. ApoE -/- mice were given a high cholesterol diet (HCD) for 12 weeks. After six weeks of HCD, intermediate atheroscleroti...
#1Maria V. Selvadurai (Monash University)H-Index: 3
#2Moeen Riaz (Monash University)H-Index: 13
Last. Justin Raymond Hamilton (Monash University)H-Index: 23
view all 7 authors...
Background null Protease-activated receptor 4 (PAR4) is a platelet thrombin receptor important for thrombosis and a target of anti-platelet drug development. A frequently occurring single nucleotide polymorphism (SNP; rs773902) causes a PAR4 sequence variant (NC_000019.10:p.Ala120Thr) whereby platelets from Thr120-expressing individuals are hyper-responsive to PAR4 agonists versus platelets from Ala120-expressing individuals. However, whether this enhanced platelet responsiveness translates to i...
#1C. Mary Schooling (HKU: University of Hong Kong)H-Index: 32
#2SL Au Yeung (HKU: University of Hong Kong)H-Index: 8
Last. Jie V. Zhao (HKU: University of Hong Kong)H-Index: 12
view all 3 authors...
Background: Statins have long been suspected to have pleiotropic effects via thrombotic factors. Randomized controlled trials are too limited to be definitive. We examined the associations of genetically mimicking effects of statins, PCSK9 inhibitors and alternative lipid targets (in genes LDLR, APOC3, and LPL) on key indicators of coagulation system function, i.e., prothrombin time (PT) and activated partial thromboplastin time (aPTT). Methods: We assessed the effect of established genetic mimi...
#1Ana BlascoH-Index: 11
Last. Carmen BellasH-Index: 27
view all 16 authors...
Aims null The mechanisms of coronary thrombosis can influence prognosis after STEMI and allow for different treatment groups to be identified; an association between neutrophil extracellular traps (NETs) and unfavorable clinical outcomes has been suggested. Our aim was to determine the role played by NETs in coronary thrombosis and their influence on prognosis. The role of other histological features in prognosis and the association between NETs and bacteria in the coronary thrombi were also exp...
#1Marianne S. Andresen (Oslo University Hospital)H-Index: 6
#2Marit Sletten (Oslo University Hospital)H-Index: 6
Last. Mari Tinholt (UiO: University of Oslo)H-Index: 8
view all 6 authors...
Most breast cancers express estrogen receptor (ER) where estrogen signaling plays an important role. Cancer contributes to activation of the coagulation system leading to an imbalance in the hemostatic system, and Coagulation factor (F) V, which is a key regulator of blood coagulation, has been shown to be increased in breast tumors. Thus, the molecular association between estrogens and FV was explored. Stimulation with 17-β-estradiol (E2) or 17-β-ethinylestradiol (EE2) resulted in a time- and d...
#2Eileen Merriman (North Shore Hospital)H-Index: 3
Last. Henry ChanH-Index: 3
view all 5 authors...
Background The recommended dose of idarucizumab, the specific reversal agent for dabigatran etexilate, is 5g. However, published data showed biochemical reversal after an initial 2.5g dose. Objectives This study aims to retrospectively compare the clinical effectiveness of 2.5g and 5g doses of idarucizumab used in dabigatran reversal in three hospitals in Auckland, New Zealand. Methods All patients receiving idarucizumab for dabigatran reversal between 1st April 2016 and 31st December 2018 were ...
#1David Green (NU: Northwestern University)H-Index: 55
The antiphospholipid syndrome is characterized by antibodies directed against phospholipid-binding proteins and phospholipids attached to cell membrane receptors, mitochondria, oxidized lipoproteins, and activated complement components. When antibodies bind to these complex antigens, cells are activated and the coagulation and complement cascades are triggered, culminating in thrombotic events and pregnancy morbidity that further define the syndrome. The phospholipid-binding proteins most often ...
Last. Theodore E. Warkentin (McMaster University)H-Index: 89
view all 7 authors...
#1Michael B. Rothberg (Cleveland Clinic)H-Index: 41
#2Aaron C Hamilton (Cleveland Clinic)H-Index: 4
Last. Bo Hu (Cleveland Clinic)H-Index: 24
view all 10 authors...
Background: Venous thromboembolism (VTE) prophylaxis is recommended for hospitalized medical patients at high risk for VTE. Multiple risk assessment models exist, but few have been compared in large data sets. Methods: We constructed a derivation cohort using 6 years of data from 13 hospitals to identify risk factors associated with developing VTE within 14 days of admission. VTE was identified using a complex algorithm combining administrative codes and clinical data. We developed a multivariab...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.